Ratcliffe W A, Hutchesson A C, Bundred N J, Ratcliffe J G
Wolfson Research Laboratories, Queen Elizabeth Medical Centre, Birmingham, UK.
Lancet. 1992 Jan 18;339(8786):164-7. doi: 10.1016/0140-6736(92)90220-w.
Parathyroid-hormone-related protein (PTHrP) has been implicated as a humoral mediator of hypercalcaemia in malignant disease. We have investigated the contributions of PTHrP and parathyroid hormone (PTH) to the hypercalcaemia seen in routine clinical practice by means of highly sensitive immunoradiometric assays. PTHrP concentrations in plasma and PTH concentrations in serum were measured in 121 consecutive patients with hypercalcaemia (corrected serum calcium above 2.65 mmol/l) identified from routine biochemical profiles in a district general hospital. Hypercalcaemia was due to primary hyperparathyroidism in 63 (52%) patients and to malignant disease in 40 (49%). Plasma PTHrP was detectable in 35 (88%) of 40 patients with solid tumours and 3 of 9 patients with haematological malignant disease; it was undetectable in 92% of patients with primary hyperparathyroidism. 7 patients with malignant disease had PTH concentrations above 4.0 pmol/l, consistent with coexisting primary hyperparathyroidism. Measurement of both PTH and PTHrP in all patients led to a change in the diagnosis in 7% of patients. This study provides direct evidence for a humoral role of tumour-derived PTHrP in hypercalcaemia, and shows how PTHrP assays can be used appropriately, in conjunction with PTH assays, to investigate hypercalcaemia in routine clinical practice.
甲状旁腺激素相关蛋白(PTHrP)被认为是恶性疾病中高钙血症的一种体液介质。我们通过高灵敏度免疫放射分析方法,研究了PTHrP和甲状旁腺激素(PTH)在常规临床实践中所见高钙血症中的作用。在一家地区综合医院,对从常规生化检查中确诊的121例高钙血症患者(校正血清钙高于2.65 mmol/L)连续进行血浆PTHrP浓度和血清PTH浓度测定。63例(52%)患者的高钙血症是由原发性甲状旁腺功能亢进引起,40例(49%)是由恶性疾病引起。40例实体瘤患者中有35例(88%)及9例血液系统恶性疾病患者中有3例血浆PTHrP可检测到;92%的原发性甲状旁腺功能亢进患者血浆PTHrP检测不到。7例恶性疾病患者的PTH浓度高于4.0 pmol/L,符合合并原发性甲状旁腺功能亢进。对所有患者同时检测PTH和PTHrP,使7%的患者诊断发生了改变。本研究为肿瘤源性PTHrP在高钙血症中的体液作用提供了直接证据,并表明在常规临床实践中,PTHrP检测如何能与PTH检测一起合理用于研究高钙血症。